| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
35,720,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile HCW Biologics is a biopharmaceutical company focused on discovering and developing immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. Co. has selected two molecules as its primary product candidates: HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the Senescence-Associated Secretory Phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9302 is designed to activate and expand regulatory T cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
54,450 |
497,616 |
| Total Buy Value |
$0 |
$0 |
$111,143 |
$1,084,632 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
15 |
49 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wong Hing C |
Chief Executive Officer |
• • – |
2021-08-30 |
4 |
B |
$3.93 |
$23,600 |
D/D |
6,000 |
15,274,118 |
2.81 |
- |
|
| Wong Hing C |
Chief Executive Officer |
• • – |
2021-08-27 |
4/A |
B |
$3.76 |
$30,100 |
D/D |
8,000 |
15,270,118 |
2.81 |
- |
|
| Wong Hing C |
Chief Executive Officer |
• • – |
2021-08-27 |
4 |
B |
$3.77 |
$22,620 |
D/D |
6,000 |
15,268,118 |
2.81 |
- |
|
| Wong Hing C |
Chief Executive Officer |
• • – |
2021-08-26 |
4 |
B |
$3.84 |
$24,970 |
D/D |
6,500 |
15,262,118 |
2.81 |
- |
|
| Greene Rick S. |
Director |
– • – |
2021-08-25 |
4 |
B |
$4.10 |
$14,821 |
D/D |
3,611 |
3,611 |
2.39 |
- |
|
| Flowers Lee |
SVP of Business Development |
• – – |
2021-08-23 |
4 |
B |
$3.95 |
$22,157 |
D/D |
5,605 |
91,667 |
2.74 |
- |
|
| Flowers Lee |
SVP of Business Development |
• – – |
2021-08-20 |
4 |
B |
$4.08 |
$32,069 |
D/D |
7,853 |
86,062 |
2.74 |
- |
|
| Flowers Lee |
SVP of Business Development |
• – – |
2021-08-19 |
4 |
B |
$4.25 |
$44,785 |
D/D |
10,532 |
78,209 |
2.74 |
- |
|
| Byam Rebecca |
Chief Financial Officer |
• – – |
2021-08-19 |
4 |
B |
$4.40 |
$43,979 |
D/D |
10,000 |
62,000 |
2.74 |
- |
|
| Garrett Scott T |
Director |
– • – |
2021-07-22 |
4 |
B |
$8.00 |
$1,000,000 |
I/I |
125,000 |
125,000 |
2.1 |
- |
|
| Medmira Capital Ltd. |
10% Owner |
– – • |
2021-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,587,661 |
3,587,661 |
|
- |
|
| Byam Rebecca |
Chief Financial Officer |
• – – |
2021-07-22 |
4 |
B |
$8.00 |
$200,000 |
D/D |
25,000 |
52,000 |
2.74 |
- |
|
| Flowers Lee |
SVP of Business Development |
• – – |
2021-07-22 |
4 |
B |
$8.00 |
$250,000 |
D/D |
31,250 |
67,677 |
2.74 |
- |
|
| Rhode Peter |
See Remarks |
• – – |
2021-07-22 |
4 |
B |
$8.00 |
$100,000 |
D/D |
12,500 |
46,785 |
2.74 |
- |
|
| Wong Hing C |
Chief Executive Officer |
• • – |
2021-07-22 |
4 |
B |
$8.00 |
$5,020,000 |
D/D |
627,500 |
15,255,618 |
2.81 |
- |
|
| Wong Hing C |
Chief Executive Officer |
• • – |
2021-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
10,342,404 |
14,628,118 |
|
- |
|
91 Records found
|
|
Page 4 of 4 |
|
|
